Literature DB >> 9776213

The prothrombin 20210 G to A variation and thrombosis.

R M Bertina1.   

Abstract

The 20210 G to A variation in the prothrombin gene was first described in 1996 and found to be associated with both elevated plasma prothrombin levels and a moderately increased risk for first venous thrombotic events. These findings generally have been confirmed in several independent studies. The 20210A allele seems to be rather common in white subpopulations, among whom the prevalence of heterozygous carriers may vary from 1% to 5%. The variant prothrombin allele contributes to the risk of thrombosis in carriers of other genetic risk factors (eg, factor V Leiden); also, this allele seems not to be an important risk factor for arterial thrombosis, unless risk factors for cardiovascular disease (eg, smoking) also are present.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9776213     DOI: 10.1097/00062752-199809000-00006

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  9 in total

Review 1.  Behçet's disease and thrombophilia.

Authors:  M Leiba; Y Sidi; H Gur; A Leiba; M Ehrenfeld
Journal:  Ann Rheum Dis       Date:  2001-12       Impact factor: 19.103

2.  Prevalence of the prothrombin G20210A polymorphism in the Lebanese population: use of a reverse hybridization strip assay approach.

Authors:  Amira S Sabbagh; Georges Ibrahim; Ziad Kanaan; Dina M R Shammaa; Rabab Abdel Khalek; Mona Ghasham; Layal Greige; Rami A R Mahfouz
Journal:  Mol Biol Rep       Date:  2007-12-08       Impact factor: 2.316

3.  Deep venous thrombosis in a patient with Behçet's disease and homozygous prothrombin (factor II) G20210A mutation on oral contraceptive pills.

Authors:  Imad Uthman; Zaher Otrock; Ali Taher
Journal:  Rheumatol Int       Date:  2005-09-28       Impact factor: 2.631

4.  Conservative mutations in the C2 domains of factor VIII and factor V alter phospholipid binding and cofactor activity.

Authors:  Gary E Gilbert; Valerie A Novakovic; Randal J Kaufman; Hongzhi Miao; Steven W Pipe
Journal:  Blood       Date:  2012-05-21       Impact factor: 22.113

5.  G20210A prothrombin gene polymorphism and coronary ischaemic syndromes: a phenotype-specific meta-analysis of 12 034 subjects.

Authors:  F Burzotta; K Paciaroni; V De Stefano; F Crea; A Maseri; G Leone; F Andreotti
Journal:  Heart       Date:  2004-01       Impact factor: 5.994

Review 6.  Clinical significance of gene-diagnosis for defects in coagulation factors and inhibitors.

Authors:  Herbert H Watzke
Journal:  Wien Klin Wochenschr       Date:  2003-08-14       Impact factor: 1.704

7.  Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C.

Authors:  Subramanian Yegneswaran; Phuong M Nguyen; Andrew J Gale; John H Griffin
Journal:  Thromb Haemost       Date:  2009-01       Impact factor: 5.249

8.  Internal jugular vein thrombosis in a warfarinised patient: a case report.

Authors:  Elizabeth Ball; Gareth Morris-Stiff; Mari Coxon; Michael H Lewis
Journal:  J Med Case Rep       Date:  2007-12-20

9.  Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.

Authors:  Elena Schiopu; Soumya Chatterjee; Vivien Hsu; Armando Flor; Daniel Cimbora; Kaushik Patra; Wenliang Yao; Jing Li; Katie Streicher; Kathleen McKeever; Barbara White; Eliezer Katz; Jorn Drappa; Sarah Sweeny; Ronald Herbst
Journal:  Arthritis Res Ther       Date:  2016-06-07       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.